Screener
Dianthus Therapeutics DNTH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $627,667 | $51,087 |
| Short-term investments | 483,592 | 353,208 |
| Accounts receivable, net | 1,230 | 52 |
| Prepaid expenses and other current assets | 7,422 | 5,091 |
| Total current assets | 1,119,911 | 409,438 |
| Long-term investments | 113,868 | 110,135 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's cash & equivalents?
- Dianthus Therapeutics (DNTH) reported cash & equivalents of $627.67M in Q1 2026.
- How has Dianthus Therapeutics's cash & equivalents changed year-over-year?
- Dianthus Therapeutics's cash & equivalents increased by 6104.7% year-over-year, from $10.12M to $627.67M.
- What is the long-term trend for Dianthus Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's cash & equivalents has grown at a -2.6% compound annual growth rate (CAGR), from $58.15M to $51.09M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Dianthus Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude